Abstract. Binding of '25I-Factor XIa to platelets required the presence of high molecular weight kininogen, was enhanced when platelets were stimulated with thrombin, and reached a plateau after 4-6 min of incubation at 370C. Factor XIa binding was specific: 50-to 100-fold molar excesses of unlabeled Factor XIa prevented binding, whereas Factor XI, prekallikrein, Factor XIIa, and prothrombin did not. When washed erythrocytes, added at concentrations calculated to provide an equivalent surface area to platelets, were incubated with Factor XIa, only a low level of nonspecific, nonsaturable binding was detected. Factor XIa binding to platelets was partially reversible and was saturable at concentrations of added Factor XIa of 0.2-0.4 ug/ml (1.25-2.5 MM).
of maximal coagulant activity occurred at 2 h of incubation, at which time >95% of the protein was present in cleavage products of molecular weight 48,000 and 32,000 (see Fig. 1 ).
Functional assays ofcoagulation proteins. Factors XI, prekallikrein, and high molecular weight kininogen were assayed using minor modifications of the kaolin-activated partial thromboplastin time (4) with appropriate congenitally deficient substrate plasmas. Factor XIa activity was estimated by a similar assay carried out in siliconized glass tubes without the addition of kaolin (4) .
Factor XIa was also assayed for amidolytic activity using the chromogenic substrate, Pyr-Glu-Pro-Arg-p-nitroanilide (S-2366), as previously described (9) , and for antigenic activity by radioimmunoassay using monospecific rabbit antihuman Factor XI, as previously described (4, 9) . The radioimmunoassay did not distinguish between Factor XI and Factor XIa and could be used to measure either protein. By comparing the results of the amidolytic assay of purified Factor XIa (127 U/ml) with those of the Factor XI coagulation assays for purified Factor XIa (135 U/ml) and with the radioimmunoassay for Factor XI (750 4g/ml), we could determine a specific activity for our Factor XIa preparation of 180 U/mg protein.
Preparation of "25-labeled Factor XIa. For binding studies, 125i
labeled Factor XI was prepared both by the procedure of Bolton and Hunter (10) and by the lodogen method (1 1). Most of free 1251I was then separated by passage through a l-ml G-25 column (12) . The labeled protein was further dialyzed in the presence of ovalbumin (1 mg/ml).
'25I-Factor XIa was prepared from the zymogen using Factor XIIa as described above. The specific radioactivity of the protein obtained by the Iodogen method was l1.1 X 106 cpm/Ag, compared with 0.5 X 106 cpm/,gg, obtained by the Bolton and Hunter procedure. More than 85% of the clotting activity of Factor XIa was retained after radiolabeling by either method. In binding experiments both proteins gave identical results. Protein analysis. Protein assays were performed according to the method of Lowry et al. (13) . Polyacrylamide slab gel electrophoresis in SDS was carried out according to the procedure of Laemmli (14) .
Preparation of platelet and erythrocyte suspensions. Platelet-rich plasma was obtained from citrated human blood and gel filtered on a Sepharose 2B column equilibrated in calcium-free Hepes Tyrode's buffer, pH 7.3, containing BSA, 1 mg/ml (15) . Platelets were counted electronically (Coulter Electronics, Inc., Hialeah, FL). A l-ml aliquot of the pellet, after removal of the platelet-rich plasma and the buffy coat, was used to make red cell suspensions. To remove plasma and contaminating platelets from the red cell suspension, it was washed five times with Hanks' balanced salt solution by centrifugation at 150 g for 10 min and finally suspended in Hepes Tyrode's buffer, pH 7.4, containing BSA (1 mg/ml). The red cells were counted microscopically and adjusted to concentrations such that total surface area of the cells per milliliter in the red cell and platelet suspensions were equivalent. Surface area for erythrocytes was assumed to be 145 Am2 (16) ; for platelets, surface area was calculated to be 18 Am2, assuming spherical shape and mean platelet volume of 7.5 fl, as determined by electronic sizing (Coulter Electronics, Inc.) in our laboratory.
Binding experiments. In a typical binding experiment, 100 Ml of gelfiltered platelets (2-4 X 108/ml) in calcium-free Hepes Tyrode's buffer, pH 7.4, were incubated at 370C in a 1.5 ml polypropylene centrifuge tube (Sarstedt, Inc., Princeton, NJ) with high molecular weight kininogen, thrombin, and radiolabeled Factor XIa in a total volume of 115 Al. In time course experiments, after incubation of appropriately expanded volumes for a specified time, I00-Ml aliquots were removed and centrifuged in a microfuge (model B; Beckman Instruments, Inc., Cedar Grove, NJ) through a mixture of silicon oils (5 vol DC550: 1 vol DC200) in microsediment tubes with narrow bore extended tips (Sarstedt, Inc., Princeton, NJ). The tips containing the sediments were amputated with wire cutters and the supernatants and sediments were counted separately in a gamma counter (model CG 4000; Intertechnique, Plaisir, France). In concentration dependency determinations, incubations were done for 5 min, before centrifugation through oil. In experiments with platelets labeled with 51Cr, >94% of the radioactivity was recovered in the pellet, thus confirming that the binding assay functioned to sediment the platelets. When platelets were incubated with "25I-labeled BSA to measure trapped volume, the fraction of radioactivity that appeared in the pellet was <0.005. When '25l-labeled Factor XIa was centrifuged over silicon oils in the absence ofplatelets, the fraction ofradioactivity that appeared in the pellet was <0.001. Therefore, the procedure used was validated as a method to separate platelets from unbound ligand.
Results
Results of polyacrylamide gel electrophoresis in SDS of purified Factor XI and Factor XIa, under both nonreducing and reducing conditions, are shown in Fig. 1 . Radiolabeling did not affect the electrophoretic behavior of either molecule. Both '25I-labeled and unlabeled Factor XI and Factor XIa migrated as 160,000-mol-wt proteins under nonreducing conditions, whereas under reducing conditions Factor XI appeared as a single band at 80,000 mol wt and Factor XIa appeared as two bands, one at 48,000 mol wt the other at 32,000 mol wt.
The time course of binding of 1251-Factor XIa to platelets is shown in Fig. 2 . When neither thrombin nor high molecular weight kininogen was present in the incubation mixture, <0.5 ng of Factor XIa was bound per 108 platelets. In contrast, when both thrombin and high molecular weight kininogen were present, Factor XIa binding progressively increased to a maximum, at 4-6 min, of '-3.5 ng/108 platelets. In the presence of thrombin alone, very little if any binding was observed, whereas in the presence of high molecular weight kininogen alone, 10-60% of maximum binding was observed in different experiments, probably reflecting partial activation of platelets during gel filtration. When ADP (10 ,uM) (Fig. 3 ). This indicated that the affinities of radiolabeled and unlabeled Factor XIa were comparable. The effect of high molecular weight kininogen concentration on the binding of Factor XIa to platelets in the presence of thrombin is shown in fig. 4 . A sigmoid curve was consistently noted in this and similar experiments, with saturation occurring at concentrations of 12-30 Ag/ml. At concentrations of high molecular weight kininogen of 50 and 100 jg/ml, binding of '251I-Factor XIa was diminished so that 62% of maximal binding was observed at 100 gg/ml of high molecular weight kininogen.
The effect of various concentrations of thrombin on the binding ofFactor XIa to platelets was examined in the presence of high molecular weight kininogen (Fig. 5) . No appreciable effect of thrombin was observed at concentrations of 0.05 U/ ml or less, whereas a plateau was observed at concentrations ranging between 0.1 and 0.3 U/ml; at higher concentrations of thrombin we observed progressively diminished binding.
To determine the specificity of binding of Factor XIa to platelets, we added a variety ofproteins, in 50-to 100-fold molar excess compared with radiolabeled Factor XIa, to platelet suspensions in the presence ofthrombin and high molecular weight kininogen (Table I) . When a 50-fold molar excess of cold Factor XIa was added to the incubation mixture that contained 0.45 jig/ml of radiolabeled Factor XIa, only 11% of control binding was observed, indicating that -89% was prevented. In contrast, when zymogen, Factor XI, was added at the same concentration as cold Factor XIa, virtually no competition was observed. Similar results were obtained when Factor XIIa, prekallikrein, and prothrombin were added in a 50-to 100-fold molar excess. XIa to platelets in the presence of high molecular weight kininogen. Gel-filtered platelets (2.68 X 108/ml) were incubated with '25I-labeled Factor XIa (0.56 zg/ml) in the presence of high molecular weight kininogen (12.5 sg/ml) and thrombin at the concentration indicated.
Binding was determined as indicated in Methods. These results indicate that the binding of Factor XIa to platelets is specific and that the binding site is distinct from that for Factor XI.
To examine further the specificity of this interaction, the characteristics of radiolabeled Factor XIa binding to red cells (added at a concentration calculated to provide a surface area equivalent to that of platelets) were determined in the presence of thrombin and high molecular weight kininogen (Fig. 1) . The time course of binding to platelets is shown in the figure; the low level ofbinding to red cells was similar to nonspecific binding to platelets. Fig. 6 demonstrates saturable binding of Factor XIa to platelets at various ligand concentrations, whereas nonsaturable, nonspecific binding to red cells was observed.
To study the reversibility of binding, gel-filtered platelets were incubated with radiolabeled Factor XIa in the presence of high molecular weight kininogen and thrombin, and after a plateau was achieved at 4 min of incubation, a 50-fold molar excess of cold Factor XIa was added to the incubation mixture to determine whether reversal of binding would occur (Fig. 7) . Rapid dissociation of bound ligand was observed, and 10 min after addition of cold Factor XIa, 35-40% of the bound ligand was displaced. No further reversal of binding was observed when incubations were carried out to 30 min.
To determine whether the binding of Factor XIa to platelets was saturable and to estimate the number and affinity ofbinding sites for Factor XIa, Factor XIa binding to thrombin activated platelets in the presence of high molecular weight kininogen was measured as a function of total concentration of Factor XIa (Fig. 6) To characterize the bound Factor XIa, platelets were incubated with high molecular weight kininogen and thrombin and centrifuged through 20% sucrose to isolate bound ligand.
When the experiment was done without added platelets, the fraction of radioactivity recovered in the pellet was <0.001. Platelet pellets were solubilized in 2% SDS and were analyzed both by 7.5% polyacrylamide gel electrophoresis in the presence of SDS and by later radioautography. More than 95% of the 1251I was solubilized and applied to the gel. The bound radioligand migrated as a 160,000-mol-wt protein on nonreduced gels and was indistinguishable from added Factor XI (data not shown). On reduced gels the bound Factor XIa migrated as two polypeptides of 48,000 and 32,000 mol wt and was again indistinguishable from free Factor XIa (Fig. 8) . This experiment provides Figure 7 . Reversibility of Factor XIa binding to activated platelets in the presence of high molecular weight kininogen. Gel-filtered platelets (3 X 108/ml) were incubated for 4 min with '25I-labeled Factor XIa (0.375 Ag/ml) in the presence of high molecular weight kininogen (12. 5 ug/ml) and thrombin (0.2 U/ml). At 4 min, 18.8 ,ug/ml of unlabeled Factor XIa (e) or of buffer (o) was added. Binding was determined at the indicated time points as indicated in Methods. Gel-filtered platelets (4.5 X 108/ml) were incubated for 8 min at 37°C with '251-labeled Factor XIa (2.5 gg/ml), high molecular weight kininogen (20 ug/ml), and thrombin (0.1 U/ml). After centrifugation through 20% sucrose, the platelet pellet was solubilized in 2.0% SDS containing 1 mM diisopropylfluorophosphate, 1 mM benzamidine, and 1 mM EDTA, and ap- (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) qg/ml) of high molecular weight kininogen that affects the extent of Factor XIa binding (Fig. 4) is lower than its normal plasma concentration (80 ytg/ml), which could therefore be expected to regulate the binding of Factor XIa to platelets. However, further studies will be required to define the exact mechanism by which high molecular weight kininogen promotes Factor XIa binding and to identify the nature of the binding site on activated platelets.
Schmaier et al. (22) have recently presented evidence that high molecular weight kininogen is present in platelets and can be secreted from platelets exposed to various agonists. The amount of high molecular weight kininogen present in platelets is -60 ng/ 108 platelets, which comprises -0.23% ofthe plasma level of 80 ,ug/ml, assuming a platelet concentration of 3 X 108 platelets/ml (22). Since the amount of high molecular weight kininogen required for half-maximal Factor XIa binding in our experiments is 10-15 qg/ml, it is clear that the amount of this protein released from platelets would not suffice. However, the local concentration of high molecular weight kininogen on the platelet surface during secretion has not been determined. Additional work will be required to ascertain the possible role of platelet high molecular weight kininogen in Factor XIa binding.
The binding of Factor XIa to platelets is rapid, reaching a plateau in 4-6 min, and is partially reversible thereafter, with -60-65% remaining bound to platelets after a 10-min incubation with a 50-fold excess of unlabeled ligand. Derivation of the number of binding sites and the affinity of ligand-receptor interaction by Scatchard analysis is based on the assumption that the interaction between ligand and receptor is reversible and that equilibrium between free and bound ligand can be demonstrated (23). As an alternative to such an analysis, we have estimated the concentration of added Factor XIa at which saturation of platelet sites appears to occur in a direct plot of bound vs. free ligand (Fig. 6) . The impression that we had approached saturation of binding sites was confirmed by the method of Klotz (17) . In a total of six similar experiments, the Factor XIa concentration at which all sites are occupied was estimated as 0.2-0.4 ,Ag/ml (1.25-2.5 nM). When the data were plotted according to the method of Scatchard (23), a dissociation constant of 3.24 nM was calculated for the data shown in Fig.  6 . Thus, since the concentration of Factor XI in human plasma is 25-38 nM (5, 24) , if 5-10% of the Factor XI were converted to Factor XIa, all the sites on activated platelets would be occupied. Our calculations, based on direct plots of data as shown in Fig. 6 , suggest that the number of specific binding sites on activated platelets is -6 ng/108 platelets (range 3.0-11.5). When the number of binding sites is calculated by Scatchard analysis for the data in Fig. 6 , the result is 8.25 ng/108 platelets, compared with 6.0 ng/ 108 platelets by direct estimate. Therefore, the total number of specific binding sites on activated platelets is -225 per platelet (range 110-450).
Characterization of bound 125I-labeled Factor XIa by polyacrylamide gel electrophoresis in SDS and by subsequent autoradiography (Fig. 8) provides evidence that the ligand bound to platelets was Factor XIa and not a contaminant. This and four similar experiments provide no evidence for the formation of high molecular weight covalent complexes or for proteolytic degradation ofbound Factor XIa by platelets, since bound Factor XIa migrates on both reduced and nonreduced gels, identically to unbound Factor XIa.
Previous studies indicate that platelets can promote the proteolytic activation of Factor XII (2), Factor XI (2), Factor X (25), prothrombin (20, 26) , and possibly also Factor IX (2, 3).
Furthermore, the kinetics ofthe Factor XIa catalyzed activation of Factor IX suggest that this may be a physiologically relevant reaction (4) . Therefore, it will be particularly important to define the physiological consequences of Factor IXa binding to platelets by direct studies of Factor IX activation.
